Looking at Geron's Research

Via Genetic Engineering News, a long release that provides some insight into aims and progress in human embryonic stem cell (hESC) research at Geron. It covers four areas: "(1) GRNOPC1, Oligodendroglial Progenitor Cells for acute spinal cord injury, (2) GRNIC1, Islet Clusters for diabetes, (3) GRNCM1, Cardiomyocytes for myocardial infarction and (4) osteoprogenitor cells for bone fractures and osteoporosis. ... Our most advanced product, GRNOPC1 for acute spinal cord injury, is in multiple IND-enabling studies. Its in vivo mechanism of action includes myelination and trophic support of damaged spinal cord neurons, resulting in significant locomotor recovery of spinal cord injured rodents. As our work progresses with other hESC-derived cell types such as cardiomyocytes, islets, hepatocytes and osteoprogenitor cells, we are hopeful that these cell types will also demonstrate significant, long-term regenerative capacity in animal models, setting the stage for clinical trials in patients."

Link: http://www.genengnews.com/news/bnitem.aspx?name=3153413


Post a comment; thoughtful, considered opinions are valued. New comments can be edited for a few minutes following submission. Comments incorporating ad hominem attacks, advertising, and other forms of inappropriate behavior are likely to be deleted.

Note that there is a comment feed for those who like to keep up with conversations.